To date, two clinical trials are ongoing to assess safety and efficacy of HER2-targeting CAR-M therapies in HER2-overexpressing tumors (NCT04660929) and in advanced HER2 + gastric cancer with peritoneal metastases (NCT06224738). The gene discussed is ERBB2; the disease is gastric cancer.